(SIX: SFZN) EGS Beteiligungen AG, a wholly-owned subsidiary of Ernst Göhner Foundation (EGS), has subscribed to two hybrid convertible bonds of Siegfried Holding AG in a total amount of 80 million Swiss francs partially financing Siegfried’s acquisition of two pharmaceutical manufacturing sites of Novartis in Spain. The bond entitles EGS Beteiligungen AG to convert the principal amounts within 5 years into shares of Siegfried Holding AG, resulting (including the shares already held) in a stake in Siegfried of about 6.6 percent. It is expected that the additional shares will be provided from Siegfried Holding AG’s treasury shares already owned now. A capital increase is not planned.
Siegfried CEO Dr. Wolfgang Wienand: “EGS Beteiligungen AG is already now a significant and valued shareholder and we are delighted that it will further build out its participation. EGS is a stable, long-term shareholder in full support of Siegfried's strategic ambitions going forward.”
Dr. Reto Suter
Chief Financial Officer
Tel. +41 62 746 11 35
Siegfried Holding AG
Untere Bruehlstrasse 4
Tel. +41 62 746 11 11
The Siegfried Group is a global life sciences company with sites in Switzerland, the USA, Malta, China, Germany and France. In 2019, the company achieved sales of 833.5 million Swiss francs and currently employs about 2500 people at nine sites on three continents. Siegfried Holding AG is publicly listed on SIX Swiss Exchange (SIX: SFZN).
Siegfried is active in manufacturing pharmaceutical APIs (and their intermediates) as well as drug products (tablets, capsules, sterile vials, ampoules, and cartridges) for the pharmaceutical industry and provides development services.